This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Grzegorz Sienski, Ph.D.
Director and Project Manager at AstraZeneca


Greg leads The Gene Editing Technologies team at AstraZeneca in Göteborg, Sweden, where he develops cutting-edge gene editing tools that enhance the understanding and manipulation of the human genome. After earning his MSc in Biotechnology from Jagiellonian University in Krakow and the Max Planck Institute for Biochemistry in Munich, Greg embarked on a PhD at IMBA in Vienna. His research during this period centered on the transcriptional silencing of transposons in fruit flies. Following his PhD, Greg joined the Whitehead Institute, delving into the molecular underpinnings of brain diseases as a Postdoctoral Fellow. Since joining AstraZeneca in 2019, he has progressed from Associate Principal Scientist to Principal Scientist, and now to Director and Project Leader. Greg is committed to leveraging gene editing technologies to improve human health."

Agenda Sessions

  • Enhancing Precision and Efficiency of In Vivo Gene Editing with Engineered PsCas9